SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced new additions to its market-leading SureSelect target-enrichment product family, which has already enabled researchers to identify more than 50 Mendelian disease-causing genes. The new products—the SureSelect Human All Exon V6, V6+UTR and V6+COSMIC—are designed to address the current limitations of exome sequencing, giving researchers better coverage of hard-to-capture regions and providing deep coverage o